Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Total Current Liabilities (2016 - 2025)

VYNE Therapeutics (VYNE) has disclosed Total Current Liabilities for 10 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities fell 83.84% year-over-year to $2.4 million, compared with a TTM value of $2.4 million through Dec 2025, down 83.84%, and an annual FY2025 reading of $2.4 million, down 83.84% over the prior year.
  • Total Current Liabilities was $2.4 million for Q4 2025 at VYNE Therapeutics, down from $5.8 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $57.6 million in Q2 2021 and bottomed at $2.4 million in Q4 2025.
  • Average Total Current Liabilities over 5 years is $13.9 million, with a median of $10.5 million recorded in 2022.
  • The sharpest move saw Total Current Liabilities soared 137.78% in 2021, then crashed 83.84% in 2025.
  • Year by year, Total Current Liabilities stood at $18.4 million in 2021, then crashed by 49.24% to $9.3 million in 2022, then dropped by 19.34% to $7.5 million in 2023, then skyrocketed by 96.59% to $14.8 million in 2024, then plummeted by 83.84% to $2.4 million in 2025.
  • Business Quant data shows Total Current Liabilities for VYNE at $2.4 million in Q4 2025, $5.8 million in Q2 2025, and $12.3 million in Q1 2025.